NCT03681951: A reported trial by GlaxoSmithKline
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03681951 |
|---|---|
| Title | A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 16, 2018 |
| Completion date | Aug. 13, 2019 |
| Required reporting date | Aug. 12, 2020, midnight |
| Actual reporting date | July 16, 2020 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |